Reduction in 90 day readmission rates utilizing ambulatory pulmonary pressure monitoring.

Content Provider	Europe PMC
Author	Valika, Ali Sulemanjee, Nasir Pedersen, Rachel Heidenreich, Debra
Abstract	AimsIn the CHAMPION (CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in New York Heart Association Functional Class III Heart Failure Patients) trial, heart failure hospitalization (HFH) rates were lower in patients with ambulatory pulmonary artery pressure (PAP) monitoring guidance. We investigated the effect of ambulatory haemodynamic monitoring on 90 day readmission rates after HFH.Methods and resultsWe retrospectively analysed patients across the Advocate Aurora Health hospital network who had undergone PAP sensor implantation between 1 October 2015 and 31 October 2019. Patients with a ventricular assist device (VAD) or transplant prior to implantation were excluded. Rates of total HFH and 30 and 90 day all‐cause readmission up to 12 months after implantation were collected, while censoring for an endpoint of heart transplantation, VAD, or death. Event rates were compared using Poisson regression. Of 459 patients included, there were 404 HFHs before and 179 after implantation. Compared with pre‐implantation, 30 day all‐cause readmission [incidence rate ratio (IRR): 0.55 (0.39–0.77), P = 0.0006] and 90 day all cause readmission rates were lower post‐implantation [IRR: 0.45 (0.35–0.58), P < 0.0001]. The effect of PAP sensor implantation on 90 day all‐cause readmission incidence rates was consistent across multiple subgroups.ConclusionsAcross a large hospital network, ambulatory haemodynamic monitoring was associated with lower HFH rates, as well as 30 and 90 day all‐cause readmission rates. This supports the utility of ambulatory PAP monitoring to improve HF management in the era of value‐based medicine.
Page Count	6
Journal	ESC Heart Failure
Volume Number	10
PubMed Central reference number	PMC9871649
Issue Number	1
PubMed reference number	36436826
e-ISSN	20555822
DOI	10.1002/ehf2.14253
Language	English
Publisher	John Wiley and Sons Inc.
Publisher Date	2022-11-27
Publisher Place	Hoboken
Access Restriction	Open
Rights License	This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. © 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Subject Keyword	30 day readmission 90 day readmission Heart failure hospitalization Heart failure readmission Pulmonary artery pressure monitoring
Content Type	Text
Resource Type	Article
Subject	Cardiology and Cardiovascular Medicine